BioLineRx Announces Pricing of $15.4 Million Underwritten Publ...
TEL AVIV, Israel, Feb. 6, 2019 /PRNewswire-AsiaNet/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has priced an underwritten public offering of 28,000,000 American Depositary Shares ("ADSs"), each represent...
Authors: LATEST ASIANET NEWS RELEASES